Home LiteratureArticle Details
PMID: 10458618 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Immune function and phenotype before and after highly active antiretroviral therapy.

Journal of acquired immune deficiency syndromes (1999) ·Vol. 21 ·No. 5 ·1999-08-15 ·Pages 376-83

Søndergaard SR, Aladdin H, Ullum H, Gerstoft J, Skinhøj P, Pedersen BK

Abstract

Immune functions represented by equal CD4 counts before and after highly active antiretroviral therapy (i.e., pre- and post-HAART) in the same HIV-infected patients, were examined. Twelve HIV-infected patients were included. Patients had equal CD4 counts pre- and post-HAART and were studied on average 30 months pre-HAART and 17 months post-HAART. Post-HAART, CD8+ T cells expressed greater amounts of CD28 (p < .02), smaller amounts of CD38 (p < .02), and a reduced proportion of CD4+CD28+ T cells expressed CD38+ (p < .01). Proliferation increased (p < 10) in lymphocyte cell cultures stimulated with pokeweed mitogens or Candida, and was correlated to expression of CD28 on T cells (p < .02). The proportion of CD3-CD16-CD56+ natural killer (NK) cells increased (p < .05) and CD3-CD16+CD56- NK cells declined (p < .01). Production of interferon-gamma increased (p < .10). The number of naive and memory T cells, the non-major histocompatibility complex (non-MHC)-restricted and HIV-specific MHC-restricted cytotoxicity and the production of macrophage inflammatory protein-1gamma were unchanged. The finding of increased expression of CD28, correlating to increased proliferation capacity, and diminished expression of CD38 on T cells, indicates that following long-term HAART, repopulation occurs with less activated cells with increased proliferative capacity. This finding may be of clinical importance in considering risk and vulnerability for progression of opportunistic infections post-HAART.

MeSH Terms
Anti-HIV Agents/therapeutic use Antigens, CD/analysis Biomarkers CD4 Lymphocyte Count Cells, Cultured Disease Progression Drug Therapy, Combination Follow-Up Studies HIV Infections/drug therapy,immunology HIV Protease Inhibitors/therapeutic use Humans Immunophenotyping Lymphocyte Activation Male T-Lymphocyte Subsets/classification,immunology Time Factors
Chemicals
Anti-HIV Agents Antigens, CD Biomarkers HIV Protease Inhibitors
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Søndergaard S R
Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark.
Aladdin H
Ullum H
Gerstoft J
Skinhøj P
Pedersen B K
Article Info
Journal
Journal of acquired immune deficiency syndromes (1999)
Abbr.
J Acquir Immune Defic Syndr
ISSN
1525-4135
Published
1999-08-15
Pages
376-83
Language
English
Region
United States
NLM ID
100892005
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com